Abstract:
Objective To evaluate the clinical efficacy and toxicity of anlotinib as second-line treatment for patients with advanced lung adenocarcinoma resistant to platinum-based chemotherapy.
Methods The study retrospectively analyszed 38 patients with advanced lung adenocarcinoma, admitted to The Second Affiliated Hospital of Fujian Medical University and the 900th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, from June 2018 to December 2018. The patients had previously received first-line combined platinum chemotherapy. Due to disease progression following treatment, targeted therapy with arrotinib was chosen. The treatment regimen was anlotinib 12 mg/day for 2 weeks, with a 1-week gap, (1 cycle:3 weeks), and the efficacy was evaluated after every 2 cycles.
Results Each patient received an average of 6.3 cycles of anlotinib. Out of all patients, 0 showed complete response, 7 showed partial response, 21 showed stable disease, and 10 showed progression disease. The objective response rate (ORR) was found to be 18.4% (7/38), and the disease control rate (DCR) was observed to be 73.7% (28/38). The progression-free survival (PFS) was 5.5 months, and median survival time (MST) was 11.4 months. Common adverse reactions included hypertension, fatigue, decreased appetite, proteinuria, and hand-and-foot skin reaction. Most patients tolerated the adverse reactions, and the incidence of grade 3/4 adverse reactions was 18.4% (7/38).
Conclusions Our results indicate that the oral administration of anlotinib is convenient, safe and efficient as a second-line treatment for patients with advanced lung adenocarcinoma resistant to platinum-based chemotherapy.
下载: